Cita APA

Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D., Issaragrisil, S., . . . Kantarjian, H. M. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia.

Chicago Style Citation

Hochhaus, A., et al. "Long-term Benefits and Risks of Frontline Nilotinib Vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-year Update of the Randomized ENESTnd Trial." Leukemia 2016.

Cita MLA

Hochhaus, A., et al. "Long-term Benefits and Risks of Frontline Nilotinib Vs Imatinib for Chronic Myeloid Leukemia in Chronic Phase: 5-year Update of the Randomized ENESTnd Trial." Leukemia 2016.